Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 295-310 , June 2007

Risk assessment in haematopoietic stem cell transplantation: Conditioning

  • Johan Aschan, MD, PhD (Associate Professor)

      Affiliations

    • Corresponding Author InformationTel.: +46 8 585 800 00; Fax: +46 8 774 87 25.

References 

  1. Jacobson LO, Marks EK, Robson MJ, et al. Effect of spleen protection on mortality following x-irradiation. The Journal of Laboratory and Clinical Medicine. 1949;34:1538–1543
  2. Main JM, Prehn RT. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. Journal of the National Cancer Institute. 1955;15:1023–1029
  3. Thomas ED, Lochte HL, Cannon JH, et al. Supralethal whole body irradiation and isologous marrow transplantation in man. The Journal of Clinical Investigation. 1959;38:1709–1716
  4. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. Parts I and II. The New England Journal of Medicine. 1975;292:832–843895–902
  5. Storb R. Preparative regimens for patients with leukemias and severe aplastic anemia (overview) – biological basis, experimental animal studies and clinical trials at the Fred Hutchinson Cancer Research Center. Bone Marrow Transplantation. 1994;14(supplement 4):S1–S3
  6. Brochstein JA, Kernan NA, Groshen S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. The New England Journal of Medicine. 1987;317:1618–1624
  7. Deeg HJ, Storb R, Longton G, et al. Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity. International Journal of Radiation Oncology, Biology, Physics. 1988;15:647–653
  8. Thomas ED, Clift RA, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. International Journal of Radiation Oncology, Biology, Physics. 1982;8:817–821
  9. Deeg HJ, Sullivan KM, Buckner CD, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplantation. 1986;1:151–157
  10. Girinsky T, Benhamou E, Bourhis JH, et al. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. Journal of Clinical Oncology. 2000;18:981–986
  11. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood. 1990;76:1867–1871
  12. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77:1660–1665
  13. Buckner CD, Rudolph R, Fefer D, et al. High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow. Cancer. 1972;29:357–365
  14. Santos GW, Owens AHJ. Allogeneic marrow transplants in cyclophosphamide treated mice. Transplantation Proceedings. 1969;1:44–46
  15. Thomas ED, Buckner CD, Storb R, et al. Aplastic anemia treated by marrow transplantation. Lancet. 1972;1:284–289
  16. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  17. Fefer A, Einstein AB, Thomas ED. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. The New England Journal of Medicine. 1974;290:1389–1393
  18. Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood. 1987;69:1015–1020
  19. Coccia PF, Strandjord SE, Warkentin PI, et al. High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood. 1988;71:888–893
  20. Powles RL, Milliken S, Helenglass G, et al. The use of melphalan in conjunction with total body irradiation as treatment for acute leukaemia. Transplantation Proceedings. 1989;21:2955–2957
  21. Schroeder H, Pinkerton CR, Powles RL, et al. High dose melphalan and total body irradiation with autologous marrow rescue in childhood acute lymphoblastic leukaemia after relapse. Bone Marrow Transplantation. 1991;7:11–15
  22. Marks DI, Forman SJ, Blume KB, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biology of Blood and Marrow Transplantation. 2006;12:438–453
  23. Petersen FB, Buckner CD, Appelbaum FR, et al. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplantation. 1992;10:83–88
  24. Spitzer TR, Peters C, Ortlieb M, et al. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children. International Journal of Radiation Oncology, Biology, Physics. 1994;29:39–44
  25. Petersen FB, Buckner CD, Appelbaum FR, et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplantation. 1989;4:617–623
  26. Riddell S, Appelbaum FR, Buckner CD, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. Journal of Clinical Oncology. 1988;6:576–582
  27. Bender-Gotze C. Late effects of allogeneic bone marrow transplantation in children. Pediatrician. 1991;18:71–75
  28. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373–3385
  29. Curtis R, Rowlings P, Deeg H, et al. Solid cancers after bone marrow transplantation. The New England Journal of Medicine. 1997;336:897–904
  30. Peters W, Henner W, Grochow L, et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Research. 1987;47:6402–6406
  31. Santos WG, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. The New England Journal of Medicine. 1983;309:1347–1353
  32. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382–1388
  33. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79:2578–2582
  34. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 1995;85:2263–2268
  35. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036–2043
  36. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83:2723–2730
  37. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–3574
  38. Ringdén O, Labopin M, Tura S, et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). British Journal of Haematology. 1996;93:637–645
  39. Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. British Journal of Haematology. 2002;119:1115–1124
  40. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood. 1993;81:2187–2193
  41. Bunin N, Aplenc R, Kamani N, et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplantation. 2003;32:543–548
  42. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Journal of Clinical Oncology. 2000;18:340–347
  43. Hassan M. The role of busulfan in bone marrow transplantation. Medical oncology (Northwood, London, England). 1999;16:166–176
  44. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemotherapy and Pharmacology. 1989;25:55–61
  45. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060
  46. Ljungman P, Hassan M, Bekassy AN, et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplantation. 1997;20:909–913
  47. Grochow LB, Krivit W, Whitley CB, et al. Busulfan disposition in children. Blood. 1990;75:1723–1727
  48. Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?. Bone Marrow Transplantation. 1994;14:759–765
  49. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biology of Blood and Marrow Transplantation. 2000;6:548–554
  50. Hassan Z, Ljungman P, Ringden O, et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplantation. 2001;27:479–485
  51. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood and Marrow Transplantation. 2002;8:493–500
  52. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplantation. 2005;36:1021–1026
  53. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–1239
  54. Barnes DW, Corp MJ, Loutit JF, et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. British Medical Journal. 1956;626–627
  55. Weiden PL, Flournoy N, Thomas ED, et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. The New England Journal of Medicine. 1979;300:1068–1073
  56. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  57. Kolb HJ, Simoes B, Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Current Opinion in Oncology. 2004;16:167–173
  58. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  59. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400
  60. Sandmaier BM, Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In:  Blume KG,  Forman SJ,  Appelbaum FR editor. Thomas' hematopoietic cell transplantation. 3rd edn.. Oxford, UK: Blackwell Publishing Ltd; 2004;p. 1164–1176
  61. Sandmaier BM, Maris M, Maloney DG, et al. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience (abstract #264). Blood. 2003;102:78–79
  62. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  63. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  64. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104:2254–2262
  65. Niederwieser D, Gentilini C, Hegenbart U, et al. Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Critical Reviews in Oncology/Hematology. 2005;56:275–281
  66. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  67. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. The New England Journal of Medicine. 2000;343:750–758
  68. Barkholt L, Bregni M, Remberger M, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Annals of Oncology. 2006;17:1134–1140
  69. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  70. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–1558
  71. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–1814
  72. Petersen FB, Deeg HJ, Buckner CD, et al. Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide–a phase I trial. International Journal of Radiation Oncology, Biology, Physics. 1992;23:1027–1032
  73. Zander AR, Berger C, Kroger N, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clinical Cancer Research. 1997;3:2671–2675
  74. Corringham R, Gilmore M, Prentice HG, et al. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer. 1983;52:1783–1787
  75. Schiffman KS, Bensinger WI, Appelbaum FR, et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplantation. 1996;17:943–950
  76. Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemotherapy and Pharmacology. 1988;22:256–262
  77. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal of Clinical Oncology. 1992;10:102–110
  78. Fields KK, Elfenbein GJ, Perkins JB, et al. Two novel high-dose treatment regimens for metastatic breast cancer–ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Seminars in Oncology. 1993;20:59–66
  79. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763

PII: S1521-6926(06)00064-8

doi: 10.1016/j.beha.2006.09.004

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 295-310 , June 2007

Article Tools